BIMZELX, known generically as bimekizumab, is a prescription medication designed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. As a humanized monoclonal antibody, BIMZELX specifically targets and inhibits the activity of interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines involved in the inflammation and development of psoriatic plaques. By blocking these cytokines, BIMZELX helps to reduce inflammation, plaque formation, and the associated symptoms, leading to an improvement in skin clearance and quality of life for patients. It is administered through subcutaneous injection and is part of a class of drugs known as biologics, which are derived from living cells to target specific components of the immune system.